Keryx Biopharmaceuticals, Inc.
NASDAQTotal Valuation
Keryx Biopharmaceuticals, Inc. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 514.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 514.09M |
Share Statistics
Keryx Biopharmaceuticals, Inc. currently has 120.38M shares outstanding.
| Shares Outstanding | 120.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 4.33, and the price-to-book ratio stands at -0.39.
| PE Ratio | N/A |
| PS Ratio | 4.33 |
| PB Ratio | -0.39 |
| P/TBV Ratio | -7.10 |
| P/FCF Ratio | -4.15 |
| P/OCF Ratio | -4.15 |
Enterprise Valuation
| EV / Sales | 5.46 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Keryx Biopharmaceuticals, Inc. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -271.68, indicating conservative leverage, while an interest coverage ratio of -608.51 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.21 |
| Quick Ratio | 0.98 |
| Debt / Equity | -271.68 |
| Debt / EBITDA | -1.68 |
| Interest Coverage | -608.51 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -55.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | -929,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Keryx Biopharmaceuticals, Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 3.06, while the 200-day moving average is 3.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 3.91 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Keryx Biopharmaceuticals, Inc. generated 94.22M in revenue and converted that into -90.84M in net income, yielding earnings per share of -0.76. EBITDA reached -87.63M, while operating income came in at -88.60M.
| Revenue | 94.22M |
| Gross Profit | 58.87M |
| Operating Income | -88.60M |
| Pretax Income | -91.77M |
| Net Income | -90.84M |
| EBITDA | -87.63M |
| EBIT | -88.60M |
| Earnings Per Share (EPS) | -0.76 |
Balance Sheet
Keryx Biopharmaceuticals, Inc. holds 41.15M in cash and equivalents against 147.30M in total debt, resulting in a net debt position of 106.16M. Total book value stands at -1.06B, with working capital of 69.31M providing operational flexibility.
| Cash & Cash Equivalents | 41.15M |
| Total Debt | 147.30M |
| Net Debt | 106.16M |
| Equity (Book Value) | -1.06B |
| Book Value Per Share | -8.82 |
| Working Capital | 69.31M |
Cash Flow
Keryx Biopharmaceuticals, Inc. produced -98.35M in operating cash flow over the past twelve months. After subtracting -133,000.00 in capital expenditures, free cash flow totaled -98.49M - equivalent to -0.82 per share.
| Operating Cash Flow | -98.35M |
| Capital Expenditures | -133,000.00 |
| Free Cash Flow | -98.49M |
| FCF Per Share | -0.82 |
Margins
Keryx Biopharmaceuticals, Inc. operates with a gross margin of 62.49, reflecting its pricing power and cost economics. The operating margin of -94.04 and net profit margin of -96.41 provide insight into operational efficiency.
| Gross Margin | 62.49 |
| Operating Margin | -94.04 |
| Pretax Margin | -97.40 |
| Profit Margin | -96.41 |
| EBITDA Margin | -93.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.28 |
| FCF Yield | -24.08 |
Scores
Keryx Biopharmaceuticals, Inc. posts an Altman Z-Score of -9.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.56 |